Εμφανίζονται 1 - 20 Αποτελέσματα από 148 για την αναζήτηση '"артериальная ригидность"', χρόνος αναζήτησης: 0,78δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Συγγραφείς: M. V. Shalygina, М. В. Шалыгина

    Συνεισφορές: Работа выполнена в рамках гранта Российского научного фонда № 24-15-00227.

    Πηγή: Rheumatology Science and Practice; Vol 63, No 1 (2025); 46-54 ; Научно-практическая ревматология; Vol 63, No 1 (2025); 46-54 ; 1995-4492 ; 1995-4484

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/3696/2428; Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi:10.14412/1995-4484-2019-452-461; Ma WT, Gao F, Gu K, Chen DK. The role of monocytes and macrophages in autoimmune diseases: A comprehensive review. Front Immunol. 24;10:1140. doi:10.3389/fimmu.2019.01140; Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: A population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022; 400(10354):733-743. doi:10.1016/S0140-6736(22)01349-6; Rezuș E, Macovei LA, Burlui AM, Cardoneanu A, Rezuș C. Ischemic heart disease and rheumatoid arthritis-two conditions, the same background. Life (Basel). 2021;11(10):1042. doi:10.3390/life11101042; Герасимова ЕВ, Попкова ТВ. Функциональные нарушения макрофагов при ревматоидном артрите и атеросклерозе. Научно-практическая ревматология. 2018;56(4):486-493. doi:10.14412/1995-4484-2018-486-493; Sircana MC, Erre GL, Castagna F, Manetti R. Crosstalk between inflammation and atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus: Is there a common basis? Life (Basel). 2024;14(6):716. doi:10.3390/life14060716; Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207. doi:10.1038/s41392-023-01452-1; Yang S, Zhao M, Jia S. Macrophage: Key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14:1080310. doi:10.3389/fimmu.2023.1080310; Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-964. doi:10.1038/nri1733; Сарбаева НН, Пономарева МН, Милякова МН. Макрофаги: разнообразие фенотипов и функций, взаимодействие с чужеродными материалами. Гены и клетки. 2016;11(1):9-17. [Sarbaeva NN, Ponomareva JV, Milyakova MN. Macrophages: Diversity of phenotypes and functions, interaction with foreign materials. Genes and Cells. 2016;11(1):9-17. (In Russ.)].; Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440. doi:10.1002/jcp.26429; Васильева ЕФ, Брусов ОС. Роль моноцитов в клеточно-молекулярных механизмах развития системного иммунного воспаления. Часть 1. Психиатрия. 2020;18(3):76-85. doi:10.30629/2618-6667-2020-18-3-76-85; Huang X, Li Y, Fu M, Xin HB. Polarizing macrophages in vitro. Methods Mol Biol. 2018;1784:119-126. doi:10.1007/978-1-4939-7837-3_12; Spiller KL, Anfang RR, Spiller KJ, Ng J, Nakazawa KR, Daulton JW, et al. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials. 2014;35(15):4477-4488. doi:10.1016/j.biomaterials.2014.02.012; Abdelaziz MH, Abdelwahab SF, Wan J, Cai W, Huixuan W, Jianjun C, et al. Alternatively activated macrophages; a double-edged sword in allergic asthma. J Transl Med. 2020;18(1):58. doi:10.1186/s12967-020-02251-w; Wang LX, Zhang SX, Wu HJ, Rong XL, Guo J. M2b macrophage polarization and its roles in diseases. J Leukoc Biol. 2019;106(2):345-358. doi:10.1002/JLB.3RU1018-378RR; Wang Q, Ni H, Lan L, Wei X, Xiang R, Wang Y. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res. 2010;20(6):701-712. doi:10.1038/cr.2010.52; Funes SC, Rios M, Escobar-Vera J, Kalergis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186-195. doi:10.1111/imm.12910; Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016;118(4):653-667. doi:10.1161/CIRCRESAHA.115.306256; Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 2010;58(5):355-364. doi:10.1007/s00005-010-0093-y; Chalmers SA, Chitu V, Herlitz LC, Sahu R, Stanley ER, Putterman C. Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. J Autoimmun. 2015;57:42-52. doi:10.1016/j.jaut.2014.11.007; Kuriakose J, Redecke V, Guy C, Zhou J, Wu R, Ippagunta SK, et al. Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis. J Clin Invest. 2019;129(6):2251-2265. doi:10.1172/JCI125116; Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, et al. Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS One. 2018;13(12):e0208132. doi:10.1371/journal.pone.0208132; Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1-9. doi:10.1016/j.clim.2019.06.009; Sung SJ, Ge Y, Dai C, Wang H, Fu SM, Sharma R, et al. Dependence of glomerulonephritis induction on novel intraglomerular alternatively activated bone marrow-derived macrophages and Mac-1 and PD-L1 in lupus-prone NZM2328 mice. J Immunol. 2017;198(7):2589-2601. doi:10.4049/jimmunol.1601565; Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: A reappraisal. Semin Arthritis Rheum. 2010;39(6):491-503. doi:10.1016/j.semarthrit.2008.11.002; Niu XL, Feng D, Hao S, KuangXY, Wu Y, Zhu GH, et al. The significance of M1/M2 macrophage-like monocytes in children with systemic lupus erythematosus. Eur J Inflammation. 2019;17. doi:10.1177/2058739218824463; Hannemann N, Apparailly F, Courties G. New insights into macrophage heterogeneity in rheumatoid arthritis. Joint Bone Spine. 2021;88(1):105091. doi:10.1016/j.jbspin.2020.105091; Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Macrophages in rheumatoid arthritis. Histol Histopathol. 2007;22:581-586. doi:10.14670/HH-22.581; Gent YY, Ahmadi N, Voskuyl AE, Hoetjes N, van Kuijk C, Britsemmer K, et al. Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis. J Rheumatol. 2014;41(11):2145-2152. doi:10.3899/jrheum.140059; Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol. 2012;10(9):e1001395. doi:10.1371/journal.pbio.1001395; Новиков АА, Александрова ЕН, Диатроптова MA, Насонов ЕЛ. Роль цитокинов в патогенезе ревматоидного артрита. Научно-практическая ревматология. 2010;48(2):71-82. doi: 14412/1995-4484-2010-1420; Soler Palacios B, Estrada-Capetillo L, Izquierdo E, Criado G, Nieto C, Municio C, et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent proinflammatory profile. J Pathol. 2015;235(3):515-526. doi:10.1002/path.4466; Dongsheng Z, Zhiguang F, Junfeng J, Zifan L, Li W. Cyclophilin A aggravates collagen-induced arthritis via promoting classically activated macrophages. Inflammation. 2017;40(5):1761-1772. doi:10.1007/s10753-017-0619-0; Wu J, He S, Song Z, Chen S, Lin X, Sun H, et al. Macrophage polarization states in atherosclerosis. Front Immunol. 2023;14:1185587. doi:10.3389/fimmu.2023.1185587; Zhang H, Dhalla NS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci. 2024;25(2):1082. doi:10.3390/ijms25021082; Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler Thromb Vasc Biol. 2019;39(8):1510-1519. doi:10.1161/ATVBAHA.119.311998; Guzmán-Martínez G, Marañón C, CYTED RIBLES Network. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Front Immunol. 2022;13:974826. doi:10.3389/fimmu.2022.974826; Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780-807. doi:10.1038/s41569-024-01045-7; Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34(6):849-863. doi:10.1007/s10557-020-07071-0; Sansonetti M, Al Soodi B, Thum T, Jung M. Macrophage-based therapeutic approaches for cardiovascular diseases. Basic Res Cardiol. 2024;119(1):1-33. doi:10.1007/s00395-023-01027-9; Semalulu T, Tago A, Zhao K, Tselios K. Managing cardiovascular risk in systemic lupus erythematosus: Considerations for the clinician. Immunotargets Ther. 2023;12:175-186. doi:10.2147/ITT.S377076; Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al.; American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American Heart Association. Hypertension. 2015;66(3):698-722. doi:10.1161/HYP.0000000000000033; Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890. doi:10.3390/ijms19071890; Jain S, Khera R, Corrales-Medina VF, Townsend RR, Chirinos JA. Inflammation and arterial stiffness in humans. Atherosclerosis. 2014;237(2):381-390. doi:10.1016/j.atherosclerosis.2014.09.011; Васюк ЮА, Иванова СВ, Школьник ЕЛ, Котовская ЮВ, Милягин ВА, Олейников ВЭ, и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016;15(2):4-19. doi:10.15829/1728-8800-2016-2-4-19; Lacolley P, Regnault V, Laurent S. Mechanisms of arterial stiffening: From mechanotransduction to epigenetics. Arterioscler Thromb Vasc Biol. 2020;40(5):1055-1062. doi:10.1161/ATVBAHA.119.313129; Новикова ДС, Попкова ТВ, Мач ЭС, Насонов ЕЛ. Ригидность артерий – интегральный показатель сердечно-сосудистого риска у больных ревматоидным артритом. Научно-практическая ревматология. 2009;47(5):38-47. doi:10.14412/1995-4484-2009-587; Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, et al. Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol. 2016;43(9):1622-1630. doi:10.3899/jrheum.160053; Cioffi G, Viapiana O, Ognibeni F, Dalbeni A, Orsolini G, Adami S, et al. Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. Eur J Prev Cardiol. 2016;23(17):1848-1859. doi:10.1177/2047487316649762; Youssef G, Allam NT, Gaber W, Afifi A, Hesham D. Increased arterial stiffness in rheumatoid arthritis and its relation to disease activity: A cross sectional study. Egypt Heart J. 2018;70(1):35-40. doi:10.1016/j.ehj.2017.11.002; Botta E, Meroño T, Saucedo C, Martín M, Tetzlaff W, Sorroche P, et al. Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis. Atherosclerosis. 2016;251:438-444. doi:10.1016/j.atherosclerosis.2016.06.009; Vázquez-Del Mercado M, Gomez-Bañuelos E, Chavarria-Avila E, Cardona-Muñoz E, Ramos-Becerra C, Alanis-Sanchez A, et al. Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: A cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article. Medicine (Baltimore). 2017;96(33):e7862. doi:10.1097/MD.0000000000007862; Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126(21):2473-2480. doi:10.1161/CIRCULATIONAHA.112.120410; Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology (Oxford). 2012;51(6):1107-1111. doi:10.1093/rheumatology/kes006; Novikova DS, Popkova TV, Lukina GV, Luchikhina EL, Karateev DE, Volkov AV, et al. The effects of rituximab on lipids, arterial stiffness and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci. 2016;31(2):202-207. doi:10.3346/jkms.2016.31.2.202; Ammar W, Taha M, Baligh E, Osama D. Assessment of vascular stiffness using different modalities in patients with systemic lupus erythematosus: A case control study. Egypt Heart J. 2020;72(1):24. doi:10.1186/s43044-020-00062-4; Ding FM, Li M, Yang X, Ye Y, Kang L, Pang H, et al. Accelerated age-related arterial stiffness in systemic lupus erythematosus patients. J Clin Rheumatol. 2016;22(8):426-433. doi:10.1097/RHU.0000000000000432; Du T, Pang H, Ding F, Ye Y, Li M, Yang X, et al. Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. Medicine (Baltimore). 2020;99(47):e23184. doi:10.1097/MD.0000000000023184; Tziomalos K, Gkougkourelas I, Sarantopoulos A, Bekiari E, Makri E, Raptis N, et al. Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. Rheumatol Int. 2017;37(2):293-298. doi:10.1007/s00296-016-3610-4; Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigó N, Català A, et al. Patients with systemic lupus erythematosus show an increased arterial stiffness that is predicted by IgM anti-β2-glycoprotein I and small dense high-density lipoprotein particles. Arthritis Care Res (Hoboken). 2019;71(1):116-125. doi:10.1002/acr.23594; Никифоров ВС, Никищенкова ЮВ. Cовременные возможности speckle tracking эхокардиографиии в клинической практике. Рациональная фармакотерапия в кардиологии. 2017;13(2):248-255. doi:10.20996/1819-6446-2017-13-2-248-255; Lo Gullo A, Rodríguez-Carrio J, Gallizzi R, Imbalzano E, Squadrito G, Mandraffino G. Speckle tracking echocardiography as a new diagnostic tool for an assessment of cardiovascular disease in rheumatic patients. Prog Cardiovasc Dis. 2020;63(3):327-340. doi:10.1016/j.pcad.2020.03.005; Brahem M, Amor HH, Sarraj R, Touil I, Kraiem S, Rouabhia R, et al. Echocardiography coupled with strain method in the screening for cardiac involvement in rheumatoid arthritis. Curr Rheumatol Rev. 2024;20(1):72-81. doi:10.2174/1573397119666230727111601; Løgstrup BB, Masic D, Laurbjerg TB, Blegvad J, Herly M, Kristensen LD, et al. Left ventricular function at two-year follow-up in treatment-naive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: A cohort study. Scand J Rheumatol. 2017;46(6):432-440. doi:10.1080/03009742.2016.1249941; Naseem M, Samir S, Ibrahim IK, Khedr L, Shahba AAE. 2-D speckle-tracking assessment of left and right ventricular function in rheumatoid arthritis patients with and without disease activity. J Saudi Heart Assoc. 2019;31(1):41-49. doi:10.1016/j.jsha.2018.10.001; Горбунова ЮН, Кириллова ИГ, Попкова ТВ, Диатроптов МЕ, Невретдинов ТИ, Лила АМ. Динамика глобальной продольной деформации миокарда левого желудочка и уровня биомаркеров крови у больных ревматоидным артритом, получающих генно-инженерные биологические препараты или ингибиторы Янус-киназ. Современная ревматология. 2023;17(5):36-42. doi:10.14412/1996-7012-2023-5-36-42; Di Minno MND, Forte F, Tufano A, Buonauro A, Rossi FW, De Paulis A, et al. Speckle tracking echocardiography in patients with systemic lupus erythematosus: A meta-analysis. Eur J Intern Med. 2020;73:16-22. doi:10.1016/j.ejim.2019.12.033

  2. 2
    Academic Journal

    Πηγή: Kardiologiia

  3. 3
    Academic Journal

    Πηγή: Tuberculosis and Lung Diseases; Том 99, № 3 (2021); 34-40 ; Туберкулез и болезни легких; Том 99, № 3 (2021); 34-40 ; 2542-1506 ; 2075-1230

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.tibl-journal.com/jour/article/view/1520/1519; Агафонова О. В., Гриценко Т. А., Богданова Ю. В., Булгакова С. В., Косякова Ю. А., Давыдкин И., Данилова О. Е., Дзюбайло А. В., Дьячков В. А., Захарова Н. О., Золотовская И. А., Колсанов А. В., Котельников Г. П., Кривова С. П., Кудлай Д. А., Купаев В. И., Куртов И. В., Лебедева Е. А., Мензул Е. В., Назаркина И. М. и др. Поликлиническая терапия: учебник / под ред. Давыдкина И. Л., Щукина Ю. В. ‒ 2-е изд., перераб. и доп. – М.: ГЭОТАР-Медиа, 2020. ‒ 840 с. ‒ ISBN 978-5-9704-5545-6.; Блинова Т. В., Страхова Л. А., Лавренюк Н. А., Умнягина И. А. Цитокиновый профиль сыворотки крови при хронической обструктивной болезни легких профессиональной этиологии в стабильной фазе болезни и его ассоциация с другими маркерами воспалительного процесса // Пульмонология. – 2015. – Т. 25, № 5. – С. 566-573. DOI:10.18093/0869-0189-2015-25-5-566-573.; Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний. Национальные клинические рекомендации / сопредседатели Е. В. Шляхто, С. В. Недогода, А. О. Конради. – СПб., 2017. – 164 с.; Кулик Е. Г., Павленко В. И., Нарышкина С. В. Ассоциация артериальной ригидности с маркерами дисфункции сосудистого эндотелия и системного воспаления при хронической обструктивной болезни легких // Бюллетень физиологии и патологии дыхания. – 2018. – Вып. 67. – С. 31-36. DOI:10.12737/article_5a9f273cb8bdc0.80232446.; Мамаев А. Н., Кудлай Д. А. Статистические методы в медицине. ‒ М.: Практическая медицина, 2021. ‒ 136 с. ISBN 978-5-98811-635-6.; Мамаева М. Г., Демко И. В., Салмина А. Б., Собко Е. А., Малиновская Н. А., Крапошина А. Ю., Гордеева Н. В., Соловьева И. А. Клинико-патогенетические особенности формирования эндотелиальной дисфункции и артериальной ригидности у больных хронической обструктивной болезнью легких // Клиническая медицина. – 2016. – Т. 94, № 2. – С. 113-120. DOI 10.18821/0023-2149-2016-94-2-113-120.; Павленко В. И., Колосов В. П., Нарышкина С. В. Особенности коморбидного течения, прогнозирование и лечение хронической обструктивной болезни легких и ишемической болезни сердца. – Благовещенск: ФГБУ «ДНЦ ФПД» СО РАМН, 2014. – 260 с.; Чазова И. Е., Жернакова Ю. В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии // Системные гипертензии. – 2019. – Т. 16, № 1. – С. 6-31. DOI:10.26442/2075082X.2019.1.190179.; Dursunoglu N., Dursunoglu D., Yıldız A. I., Uludag B., Alaсam Z. N., Sarıсopur A. Severity of coronary atherosclerosis in patients with COPD // Clin. Respir. J. – 2017. – Vol. 11, № 6. – P. 751-756. DOI:10.1111/crj.12412.; Global strategy for the diagnosis, management and prevention of COPD, Global initiative for Chronic Obstructive Lung Disease (GOLD), 2017. [Электронный ресурс]URL: https://goldcopd.org.; Hillege H. L., Fidler V., Diercks G. F., van Gilst W. H., de Zeeuw D., van Veldhuisen D. J., Gans R. O., Janssen W. M., Grobbee D. E., de Jong P. E. Urinary albumin excretion predicts cardiovascular and noncardiovascularmortality in general population // Circulation. – 2002. – Vol. 106, № 14. – P. 1777-1782. DOI:10.1161/01.cir.0000031732.78052.81.; Jassal S. K., Langenberg C., von Muhlen D., Bergstrom J., Barett-Connor E. Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men > 40 tears of age (from the Rancho Bernardo Study) // Am. J. Cardiol. – 2008. – Vol. 101, № 9. – P. 1275-1280. DOI:10.1016/j.amjcard.2007.12.030.; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease // Kidney Inter. Suppl. – 2013. – Vol. 3, № 1. – P. 1-150. DOI:10.1038/kisup.2012.48.; Shayo F. K., Lutale J. Albuminuria in patients with chronic obstructive pulmonary disease: a cross-sectional study in an African patient cohort // BMC Pulm Med. – 2018. – № 18. – P. 125. DOI:10.1186/s12890-018-0694-5.; Sin D. D., Wu L., Man S. F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature // Chest. – 2005. – Vol. 127, № 6. – P. 1952-1959. DOI:10.1378/chest.127.6.1952.; Zhang X. L., Chi Y. H., Wang le F., Wang H. S., Lin X. M. Systemic inflammation in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention // Respirology. – 2014. – Vol. 19, № 5. – P. 723-729. DOI:10.1111/resp.12295.

  4. 4
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 17, No 1 (2021); 42-48 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 1 (2021); 42-48 ; 2225-3653 ; 1819-6446

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/2387/2110; Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский Кардиологический Журнал. 2018;(6):7-122. DOI:10.15829/1560-4071-2018-6-7-122.; Pencina M.J., D'Agostino R.B. Sr., Larson M.G., et al. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation. 2009;119(24):3078-84. DOI:10.1161/CIRCULATIONAHA.108.816694.; Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50-103. DOI:10.1016/j.jacc.2010.09.001.; Троицкая Е.А., Вельмакин С.В., Кобалава Ж.Д. Концепция сосудистого возраста: новый инструмент оценки сердечно-сосудистого риска. Артериальная Гипертензия. 2017;23(2):160-71.; Sehgel N.L., Vatner S.F., Meininger G.A. "Smooth Muscle Cell Stiffness Syndrome"-Revisiting the Structural Basis of Arterial Stiffness. Front Physiol. 2015;6:335. DOI:10.3389/fphys.2015.00335.; Safar M.E., Asmar R., Benetos A., et al. French Study Group on Arterial Stiffness. Interaction between hypertension and arterial stiffness: an expert reappraisal. Hypertension. 2018;72(4):796-805. DOI:10.1161/HYPERTENSIONAHA.118.11212.; Mancia G., de Backer G., Dominiczak A. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25(6):1105-87. DOI:10.1097/HJH.0b013e3281fc975a.; Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281- 357. DOI:10.1097/01.hjh.0000431740.32696.cc.; Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.; Ohyama Y., Ambale-Venkatesh B., Noda C., et al. Aortic Arch Pulse Wave Velocity Assessed by Magnetic Resonance Imaging as a Predictor of Incident Cardiovascular Events: The MESA (MultiEthnic Study of Atherosclerosis). Hypertension. 2017;70(3):524-30. DOI:10.1161/HYPERTENSIONAHA.116.08749.; Verwoert G.C., Elias-Smale S.E., Rizopoulos D., et al. Does aortic stiffness improve the prediction of coronary heart disease in elderly? The Rotterdam Study. J Hum Hypertens. 2012;26(1):28-34. DOI:10.1038/jhh.2010.124.; Ben-Shlomo Y., Spears M., Boustred C., et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636-46. DOI:10.1016/j.jacc.2013.09.063.; Paradkar N., Chowdhury S.R. Coronary artery disease detection using photoplethysmography. 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); July 2017; Jeju Island, Republic of Korea. P. 100-3.; Hong K.S., Park K.T., Ahn J.M. Aging Index using Photoplethysmography for a Healthcare Device: Comparison with Brachial-Ankle Pulse Wave Velocity. Healthc Inform Res. 2015;21(1):30-4. DOI:10.4258/hir.2015.21.1.30.; Парфенов А.С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратнопрограммного комплекса «Ангиоскан-01». Поликлиника. 2012;(21):70-4.; Orlova I.A., Nuraliev E.Y., Yarovaya E.B., Ageev F.T. Prognostic value of changes in arterial stiffness in men with coronary artery disease. Vasc Health Risk Manag. 2010;6:1015-21. DOI:10.2147/VHRM.S13591.; Kaess B.M., Rong J., Larson M.G., et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875-81. DOI:10.1001/2012.jama.10503.; Ecobici M., Stoicescu C. Arterial stiffness and hypertension - which comes first? Maedica (Buchar). 2017;12(3):184-90.; Laurent S., Katsahian S., Fassot C. et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34(5):1203-06. DOI:10.1161/01.STR.0000065428.03209.64.; Васюк Ю.А., Иванова С.В., Школьник Е.Л., и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная Терапия и Профилактика. 2016;15(2):4-19. DOI:10.15829/1728-8800-2016-2-4-19.; Wilkinson I.B., McEniery C.M., Cockcroft J.R. Arteriosclerosis and atherosclerosis: guilty by association. Hypertension. 2009;54(6):1213-5. DOI:10.1161/HYPERTENSIONAHA.109.142612.; Mottram P.M., Haluska B.A., Leano R., et al. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart. 2005;91(12):1551-6. DOI:10.1136/hrt.2004.046805.; van Popele N.M., Grobbee D.E., Bots M.L., et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 2001;32(2):454-60. DOI:10.1161/01.str.32.2.454.; O’Rourke M.F. Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol. 2001;38(3):803-5. DOI:10.1016/s0735-1097(01)01452-8.; Mitchell G.F., Vasan R.S., Keyes M.J. et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297(7):709-15. DOI:10.1001/jama.297.7.709.; Шупенина Е.Ю., Васюк Ю.А., Хадзегова А.Б. и др. Сравнительная оценка влияния основных классов антигипертензивных препаратов на жесткость аорты у больных артериальной гипертензией. Кардиоваскулярная Терапия и Профилактика. 2014;13(2):76-9. DOI:10.15829/1728-8800-2014-2-76-79.; Sacre J.W., Jennings G.L., Kingwell B.A. Exercise and dietary influences on arterial stiffness in cardiometabolic disease. Hypertension. 2014;63(5):888-93. DOI:10.1161/HYPERTENSIONAHA.113.02277.; https://www.rpcardio.com/jour/article/view/2387

  5. 5
    Academic Journal

    Πηγή: The Russian Archives of Internal Medicine; Том 11, № 4 (2021); 284-291 ; Архивъ внутренней медицины; Том 11, № 4 (2021); 284-291 ; 2411-6564 ; 2226-6704

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.medarhive.ru/jour/article/view/1272/1033; https://www.medarhive.ru/jour/article/view/1272/1047; Эрдес Ш.Ф., Ребров А.П., Дубинина Т.В., и др. Спондилоартриты: современная терминология и определения. Терапевтический архив. 2019; 91(5): 84–8. doi:10.26442/00403660.2019.05.000208 Erdes S.F., Rebrov A.P., Dubinina T.V. et al. Spondyloarthritis: modern terminology and definitions. Ter Arkh. 2019; 91(5): 84–8. doi:10.26442/00403660.2019.05.000208 [in Russian].; Mathieu S., Pereira B., Soubrier M. Cardiovascular events in ankylosing spondylitis: An updated meta-analysis. Semin Arthritis Rheum. 2015; 44: 551–5. doi:10.1016/j.semarthrit.2014.10.007.; Szabo S.M., Levy A.R., Rao S.R., et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population-based study. Arthritis Rheum. 2011; 63: 3294–304. doi:10.1002/art.30581.; Tomáš L., Lazúrová I., Pundová L., et al. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol. 2013; 32: 61–6. doi:10.1007/s10067-012-2091-4.; Niccoli L., Nannini C., Cassarà E., et al. Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring antiTNFα drugs and therapy-induced changes. Int J Rheum Dis. 2012; 15: 56–61. doi:10.1111/j.1756-185X.2011.01662.x.; Сафарова К.Н., Дорогойкина К.Д., Ребров А.П. Является ли анемия клиническим маркером НПВП-индуцированного поражения верхних отделов желудочно-кишечного тракта у пациентов со спондилоартритами? Альманах клинической медицины. 2019; 47(5): 410–18. doi:10.18786/2072-0505-2019-47-037. Safarova K.N., Dorogoykina K.D., Rebrov A.P. Is anemia a clinical marker of NSAIDs-induced upper gastrointestinal lesions in patients with spondyloarthritis? Almanac of Clinical Medicine. 2019; 47(5): 410–18. doi:10.18786/2072-0505-2019-47-037 [in Russian].; Zviahina O V., Shevchuk S V., Kuvikova IP, Segeda IS. Anemia in patients with ankylosing spondylitis, association with the activity of the inflammatory process and the severity of the disease. Wiad Lek. 2020; 73: 715–21. doi:10.36740/WLek202004117.; Prati C., Demougeot C., Guillot X., et al. Vascular involvement in axial spondyloarthropathies. Jt Bone Spine. 2019; 86: 159–63. doi:10.1016/j.jbspin.2018.05.003.; Bodnár N., Kerekes G., Seres I., et al. Assessment of Subclinical Vascular Disease Associated with Ankylosing Spondylitis. J Rheumatol. 2011; 38: 723–9. doi:10.3899/jrheum.100668.; Гайдукова И.З., Ребров А.П., Хондкарян Э.В. и др. Жесткость сосудистой стенки у пациентов с анкилозирующим спондилитом, принимающих нестероидные противовоспалительные препараты. Современная ревматология. 2016; 10(3): 41-46. doi:10.14412/1996-7012-2016-3-41-46. Gaidukova I.Z., Rebrov A.P., Khondkaryan E.V. et al. Vessel wall stiffness in ankylosing spondylitis patients taking nonsteroidal anti-inflammatory drugs. Modern Rheumatology Journal. 2016;10(3):41-46. doi:10.14412/1996-7012-2016-3-41-46 [in Russian].; Bai R., Zhang Y., Liu W., et al. The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systemic Review and Meta-Analysis. Angiology. 2019; 70: 492–500. doi:10.1177/0003319718814309.; Sieper J., Rudwaleit M., Baraliakos X., et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68:ii1–44. doi:10.1136/ard.2008.104018.; Levey A.S., Stevens L.A., Schmid C.H., et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009; 150: 604. doi:10.7326/0003-4819-150-9-200905050-00006.; Touboul P.-J., Hennerici M.G., Meairs S., et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004-2006-2011). Cerebrovasc Dis. 2012; 34: 290–6. doi:10.1159/000343145.; Yuan Y., Yang J., Zhang X., et al. Carotid intima-media thickness in patients with ankylosing spondylitis: A systematic review and updated meta-analysis. J Atheroscler Thromb. 2019; 26: 260–71. doi:10.5551/JAT.45294.; Paino I.M.M., Miranda J.C., Marzocchi-Machado C.M., et al. Phagocytosis, oxidative burst, and produced reactive species are affected by iron deficiency anemia and anemia of chronic diseases in elderly. Biol Trace Elem Res. 2009; 129: 116–25. doi:10.1007/s12011-008-8303-8.; Arida A., Protogerou A.D., Kitas G.D. et al. Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018; 19: 1–27. doi:10.3390/ijms19071890.; Gimbrone M.A., García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016; 118: 620–36. doi:10.1161/CIRCRESAHA.115.306301.; Schwarz C.P., Koppelstaetter C., Amann E., Mayer G. Impact of anemia on aortic pulse wave velocity in hemodialysis patients. Kidney Blood Press Res. 2009; 32: 210–6. doi:10.1159/000227274.; Hsu H.-C., Robinson C., Norton G.R., et al. The Optimal Haemoglobin Target in Dialysis Patients May Be Determined by Its Contrasting Effects on Arterial Stiffness and Pressure Pulsatility. Int J Nephrol Renovasc Dis. 2020; 13: 385–95. doi:10.2147/IJNRD.S285168.; Kishimoto S., Maruhashi T., Kajikawa M., et al. Hematocrit, hemoglobin and red blood cells are associated with vascular function and vascular structure in men. Sci Rep. 2020; 10: 11467. doi:10.1038/s41598-020-68319-1.; Arnold N., Gori T., Schnabel R.B., et al. Relation between Arterial Stiffness and Markers of Inflammation and Hemostasis — Data from the Population-based Gutenberg Health Study. Sci Rep. 2017; 7: 1–10. doi:10.1038/s41598-017-06175-2.; Sun P., Jia J., Fan F., et al. Hemoglobin and erythrocyte count are independently and positively associated with arterial stiffness in a community-based study. J Hum Hypertens. 2021; 35: 265–73. doi:10.1038/s41371-020-0332-6.; Kawamoto R., Tabara Y., Kohara K., et al. A slightly low hemoglobin level is beneficially associated with arterial stiffness in Japanese community-dwelling women. Clin Exp Hypertens. 2012; 34: 92–8. doi:10.3109/10641963.2011.618202.; Chirinos J.A., Segers P., Hughes T., Townsend R. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 74: 1237–63. doi:10.1016/j.jacc.2019.07.012.; https://www.medarhive.ru/jour/article/view/1272

  6. 6
  7. 7
  8. 8
  9. 9
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 16, No 3 (2020); 356-362 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 3 (2020); 356-362 ; 2225-3653 ; 1819-6446

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/2216/1983; Townsend N., Wilson L., Bhatnagar P., et al. Cardiovascular disease in Europe: Epidemiological update 2016. Eur Heart J. 2016;37(42):3232-45. DOI:10.1093/eurheartj/ehw334.; Троицкая Е.А., Вельмакин С.В., Кобалава Ж.Д. Концепция сосудистого возраста: новый инструмент оценки сердечно-сосудистого риска. Артериальная Гипертензия. 2017;23(2):160-71.; Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. DOI:10.1097/01.hjh.0000431740.32696.cc.; Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.; Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский Кардиологический Журнал. 2018;(6):7-122. DOI:10.15829/1560-4071-2018-6-7-122.; Tesauro M., Mauriello A., Rovella V., et al. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):471-82. DOI:10.1111/joim.12605.; Nilsson P.M. Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag. 2008;4(3):547-52. DOI:10.2147/vhrm.s1094.; Said M.A., Eppinga R.N., Lipsic E., et al. Relationship of Arterial Stiffness Index and Pulse Pressure With Cardiovascular Disease and Mortality. J Am Heart Assoc. 2018;7(2):e007621. DOI:10.1161/JAHA.117.007621; Vlachopoulos C., Aznaouridis K., Terentes-Printzios D., et al. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60(2):556-62. DOI:10.1161/HYPERTENSIONAHA.112.194779.; Hong K.S., Park K.T., Ahn J.M. Aging Index using Photoplethysmography for a Healthcare Device: Comparison with Brachial-Ankle Pulse Wave Velocity. Healthc Inform Res. 2015;21(1):30-4. DOI:10.4258/hir.2015.21.1.30.; Парфенов А.С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратно-программного комплекса «Ангиоскан-01». Поликлиника. 2012;21:70-4.; Soureti A., Hurling R., Murray P., et al. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;1(5):519-23. DOI:10.1097/HJR.0b013e328337ccd3.; toboz-Rudnicka M., Jaroch J., Bociqga Z. et al. Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness. Cardiol J. 2013;20(4):394-401. DOI:10.5603/CJ.2013.0098.; Laurent S., Marais L., Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669-79. DOI:10.1016/j.cjca.2016.01.039.; Cunha P.G., Olsen M.H. Chapter 24. Vascular Aging and Cardiovascular Disease. In: Nilsson P.M., Olsen M.H., Laurent S., eds. Early Vascular Aging (EVA). New Directions in Cardiovascular Protection. London, UK: Academic Press; 2015: 261-71. DOI:10.1016/B978-0-12-801387-8.00025-9.; Kawasaki T., Sasayama S., Yagi S., et al. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res. 1987;21:678-87. DOI:10.1093/cvr/21.9.678.; Ecobici M., Stoicescu C. Arterial stiffness and hypertension - which comes first? Maedica (Bu-char). 2017;12(3):184-90.; Benetos A., Adamopouolos C., Bureau J.M., et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105(10):1202-7. DOI:10.1161/hc1002.105135.; Doonan R., Hausvater A., Scallan C., et al. The effect of smoking on arterial stiffness. Hypertens Res. 2010;33(5):398-410. DOI:10.1038/hr.2010.25.; Oncken C.A., White W.B., Cooney J.L., et al. Impact of smoking cessation on ambulatory blood pressure and heart rate in postmenopausal women. Am J Hypertens. 2001;14(9):942-9. DOI:10.1016/s0895-7061(01)02147-1.; Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-30. DOI:10.1016/j.jacc.2007.10.038.; Kawakami A., Osaka M., Tani M., et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation. 2008;118(7):731-42. DOI:10.1161/CIRCULATIONAHA.108.784785.; Wang X., Ye P., Cao R., et al. Triglycerides are a predictive factor for arterial stiffness: a communitybased 4.8-year prospective study. Lipids Health Dis. 2016;15:97. DOI:10.1186/s12944-016-0266-8.; Safar M.E., Czernichow S., Blacher J. Obesity, Arterial Stiffness, and Cardiovascular Risk. JASN. 2006;17(4):109-11. DOI:10.1681/ASN.2005121321.; Paffenbarger R.S. Jr, Jung D.L., Leung R.W., Hyde R.T. Physical activity and hypertension: an epidemiological view. Ann Med. 1991;(23):319-27. DOI:10.3109/07853899109148067.; https://www.rpcardio.com/jour/article/view/2216

  10. 10
    Academic Journal

    Πηγή: Obstetrics, Gynecology and Reproduction; Vol 14, No 4 (2020); 479-489 ; Акушерство, Гинекология и Репродукция; Vol 14, No 4 (2020); 479-489 ; 2500-3194 ; 2313-7347

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.gynecology.su/jour/article/view/796/836; Newson L. Menopause and cardiovascular disease. Post Reprod Health. 2018;24(1):44–9. https://doi.org/10.1177/2053369117749675.; Stefanska A., Bergmann K., Sypniewska G. Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance. Adv Clin Chem. 2015;72:1–75. https://doi.org/10.1016/bs.acc.2015.07.001.; Юренева С.В., Ильина Л.М. Старение репродуктивной системы женщин: от теории к клинической практике. Часть II. Роль гормональной терапии в решении проблем переходного периода и ранней постменопаузы. Акушерство и гинекология. 2014;(4):17–24.; Baber R.J., Panay N. Fenton A. and the IMS Writing Group NS 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.; Laurent S., Cockcroft J., Van Bortel L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605. https://doi.org/10.1093/eurheartj/ehl254.; Vlachopoulos C., Xaplanteris P., Aboyans V. et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241:507–32. https://doi.org/10.1016/j.atherosclerosis.2015.05.007.; Regnault V., Thomas F., Safar M.E. et al. Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol. 2012;15;59(20):1771–7. https://doi.org/10.1016/j.jacc.2012.01.044.; Bordin Pelazza B., Filho S.R.F. Comparison between central and brachial blood pressure in hypertensive elderly women and men. Int J Hypertens. 2017;2017:6265823. https://doi.org/10.1155/2017/6265823.; Толстов С.Н., Салов И.А., Ребров А.П. Структурно-функциональные изменения сосудов у женщин в ранней постменопаузе, возможности коррекции выявленных нарушений. Кардиология. 2018;58(S1):56–64. https://doi.org/10.18087/cardio.2425.; Kaess B.M., Rong J., Larson M.G. et al. Relations of central hemodynamics and aortic stiffness with left lentricular structure and function: The Framingham Heart Study. J Am Heart Assoc. 2016;5(3):e002693. https://doi.org/10.1161/JAHA.115.002693.; Williams B., Lacy P.S., Baschiera F. et al. Clinical trial: the ambulatory central aortic pressure (AmCAP) study blood pressure and the impact of blood pressure treatment in a randomized controlled novel description of the 24-hour circadian rhythms of brachial versus central aortic. Hypertension. 2013;61(6):1168–76. https://doi.org/10.1161/HYPERTENSIONAHA.111.00763.; Sarafidis P.A., Loutradis C., Karpetas A. et al. Ambulatory pulse wave velocity is a stronger pedictor of cardiovascular events and all-cause mortality than office and ambulatory blood pressure in hemodialysis patients. Hypertension. 2017;70(1):148–57. https://doi.org/10.1161/HYPERTENSIONAHA.117.09023.; https://www.gynecology.su/jour/article/view/796

  11. 11
  12. 12
  13. 13
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 57, No 3 (2019); 312-317 ; Научно-практическая ревматология; Vol 57, No 3 (2019); 312-317 ; 1995-4492 ; 1995-4484

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2732/1848; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical recommendations. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.].; Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31:612-20. 3. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358-65. doi:10.1097/MD.0b013e3181c10773; Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161-6. doi:10.3899/jrheum.090667; Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi:10.1186/s12891-015-0532-3; Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017 Feb;76(2):364-70. doi:10.1136/annrheumdis-2016-209315; Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5. doi:10.1136/ard.2011.151191; Atzeni F, Dorea A, Nurmohamed M, Pauletto P. The Heart in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases. 2017. Vol. 14. ISBN: 978-0-12-803997-7; Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality. A population-based study. Ann Intern Med. 2015 Sep 15;163(6):409-16. doi:10.7326/M14-2470; Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:557-63. doi:10.1002/acr.20364; Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi:10.1016/j.jacc.2009.09.009; Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007;100:32-40. doi:10.1016/j.amjcard.2007.08.011; Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with noninflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005;109:171-6. doi:10.1042/CS20040326; Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-304. doi:10.1002/art.30581; Maia DG, Augusto KL, Bezerra MC, Rodrigues CEM. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol. 2017;36(10):2371-6. doi:10.1007/s10067-017-3623-8; Arida A, Protogerou AD, Konstantonis G, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol. 2015;42(11):2098-105. doi:10.3899/jrheum.150316; Bodnar N, Kerekes G, Seres I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol. 2011;38(4):723-9. doi:10.3899/jrheum.100668; Yuan Y, Yang J, Zhang X, et al. Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis. J Atheroscler Thromb. 2018;25:000-000. doi:10.5551/jat.45294; Tam LS, Shang Q, Kun EW, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis – a randomized, placebo-controlled pilot trial. Rheumatology (Oxford). 2014;53:1065-74. doi:10.1093/rheumatology/ket469; Van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68:362-6. doi:10.1136/ard.2007.086777; Van Sijl AM, van Eijk IC, Peters MJL, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:119-23. doi:10.1136/annrheumdis-2013-203934; Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010;55:333-8. doi:10.1161/HYPERTENSIONAHA.109.143982; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi:10.1136/annrheumdis-2016-210770; Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47:1203-7. doi:10.1093/rheumatology/ken198; Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford). 2012;51:910-4. doi:10.1093/rheumatology/ker434; Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford). 2013;52:204-9. doi:10.1093/rheumatology/kes272; Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(Прил. 2):64 с. [Cardiovascular prevention: national guidelines. Cardiovascular therapy and prevention. 2011;10(Suppl. 2): 64 p. (In Russ).].; Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345-52.; Парфeнов АС. Экспресс-диагностика сердечно-сосудистых заболеваний. Мир измерений. 2008;(6):74-82 [Parfenov AS. Express diagnostics of cardiovascular diseases. Mir Izmerenii. 2008;(6):74-82 (In Russ.)].; Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84 [Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):474-84 (In Russ.)]. doi:10.14412/1995-4484-2017-474-484; Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4(4):CD005468. doi:10.1002/14651858.CD005468.pub2; Чичасова НВ. Значение иммуногенности при лечении ревматических заболеваний ингибиторами фактора некроза опухоли α. Современная ревматология. 2015;9(4):4-12 [Chichasova NV. Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(4):4-12 (In Russ.)]. doi:10.14412/1996-7012-2015-4-4-12; Каратеев ДЕ. Факторы, определяющие длительный успех терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2015;9(3):54-60 [Karateev DE. Factors determining long-term success of biologic therapy in rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(3):54-60 (In Russ.)]. doi:10.14412/1996-7012-2015-3-54-60; Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016;96:207-12. doi:10.2340/00015555-2214; Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10. 1016/j.pharmthera.2007.10.001

  14. 14
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 57, No 6 (2019); 647-650 ; Научно-практическая ревматология; Vol 57, No 6 (2019); 647-650 ; 1995-4492 ; 1995-4484

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2800/1901; Балабанова РМ, Дубинина ТВ, Эрдес ШФ. Динамика заболеваемости ревматическими заболеваниями взрослого населения России за 2010-2014 гг. Научно-практическая ревматология. 2016;54(3):266-70. doi:10.14412/1995-4484-2016-266-270; Маслянский АЛ, Звартау НЭ, Колесова ЕП и др. Оценка функционального состояния эндотелия у больных ревматологическими заболеваниями. Артериальная гипертензия. 2015;21(2):168-80; Divecha H, Naveed S, Rumley А, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci. 2005;109:171-6. doi:10.1042/CS20040326; Гайдукова ИЗ, Ребров АП. Риск появления ишемической болезни сердца у больных анкилозирующим спондилитом (болезнью Бехтерева) и псориатическим артритом по результатам десятилетнего проспективного наблюдения (исследование Прогресс). Клиницист. 2016;10(3):26-9 doi:10.17650/1818-8338-2016-10-3-26-31; Brophy S, Cooksey R, Atkinson M, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis — a retrospective cohort study using routine data. Semin Arthritis Rheum. 2012;42(2):140-5. doi:10.1016/j.semarthrit.2012.02.008; Han C, Robinson DW, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol. 2006;33(11):2167-72.; Haroon NN, Paterson JM, Li P, et al. Рatients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409-16. doi:10.7326/M14-2470; Лукьянов ММ, Бойцов СА. Жесткость артериальной стенки как фактор сердечно-сосудистого риска и прогноза в клинической практике. Сердце. 2010;9(3):156-9; Милягин ИВ, Филичкин ЕД, Шпынев КВ и др. Контурный анализ центральной и периферической пульсовой волн у здоровых людей и больных артериальной гипертензией. Артериальная гипертензия. 2009;15(1):78-85; Аксенова ТА, Иващенко НФ, Царенок СЮ. Центральное аортальное давление и артериальная ригидность у больных анки-лозирующим спондилоартритом при суточном мониторировании. Забайкальский медицинский вестник. 2016;(3):52-9; Laurent S, Cockcroft J, van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issuesand clinical applications. Eur Heart J. 2006;27:2588-605. doi:10.1093/eurheartj/ehl254; Becerra RC, Cardona-Mu ller D, Cardona-Munoz E, et al. Evaluation of Central Aortic Blood Pressure and Pulse Wave Velocity in subjects with Ankylosing Spondylitis compared with healthy controls. JHypertens. 2018;36:259. doi:10.1097/01.hjh.0000549060.86862.99; Karkucac M, Capkin E, Kiris A. Arterial stiffness and anti-tumor necrosis factoralpha therapy in ankylosing spondylitis: results with long-term two year follow-up. Arch Rheumatol. 2014;29(4):250-6. doi:10.5606/ArchRheumatol.2014.4261; Tam L-S, Shang Q, Kun EW, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis -a randomized, placebo-controlled pilot trial. Rheumatology (Oxford). 2014 Jun;53(6):1065-74. doi:10.1136/annrheumdis-2013-eular.1539; Гуреева НА, Горяйнов ИИ, Степченко МА. Изменения параметров жесткости артериального русла у больных болезнью Бехтерева на фоне лечения инфликсимабом. Вестник новых медицинских технологий. 2012;21(4):26-8

  15. 15
  16. 16
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 55, No 6 (2017); 637-640 ; Научно-практическая ревматология; Vol 55, No 6 (2017); 637-640 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20176

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2468/1638; Сметник ВП, Ильина ЛМ. Особенности факторов риска сердечно-сосудистых заболеваний у женщин и роль половых гормонов. Климактерий. 2007;(3):4 [Smetnik VP, Il’ina LM. Features of risk factors for cardiovascular disease in women and the role of sex hormones. Klimakteriy. 2007;(3):4 (In Russ.)].; Шальнова СА, Деев АД. Тенденции смертности в России в начале XXI века по данным официальной статистики. Кардиоваскулярная терапия и профилактика. 2011;10(6):5-10 [Shal’nova SA, Deyev AD. Mortality trends in Russia at the beginning of the 21st century according to official statistics. Kardiovaskulyarnaya Terapiya i Profilaktika. 2011;10(6):5-10 (In Russ.)].; Прохорович ЕА, Ткачева ОН, Адаменко АН, Шумбутова АЮ. Артериальная гипертония у женщин репродуктивного возраста. Русский медицинский журнал. 2007;15(20):1440-2 [Prokhorovich EA, Tkacheva ON, Adamenko AN, Shumbutova AYu. Arterial hypertension in women of reproductive age. Russkii Meditsinskii Zhurnal. 2007;15(20):1440-2 (In Russ.)].; Милягина ИВ. Клиническое значение определения эластических свойств сосудов и уровней артериального давления в различных сосудистых бассейнах у больных артериальной гипертензией. Автореф. дисс. . докт. меж. наук. Смоленск; 2008.; с. [Milyagina IV. Klinicheskoye znacheniye opredeleniya elasticheskikh svoystv sosudov i urovney arterialуnogo davleniya v razlichnykh sosudistykh basseynakh u bolуnykh arterialуnoy gipertenziyey: Avtoreferat diss. . dokt. med. nauk [Clinical significance of determining the elastic properties of blood vessels and blood pressure levels in various vascular pools in patients with arterial hypertension. Author's abstract. diss. . Doct. med. science]. Smolensk; 2008. 42 p.].; McFarlane SI, Muniyappa R, Shin JJ, et al. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine. 2004;23(1):1-10. doi:10.1385/endo:23:1:01; Browner WS, Sooley DG, Vogt TM. Non-trauma mortality in elderly women with low bone mineral density. Lancet. 1991;338:335-8. doi:10.1016/0140-6736(91)90489-c; Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women.J Bone Miner Res. 2005;20(11):1912-20. doi:10.1359/JBMR.050711; Князева ЛИ, Шишова АС, Степченко МА. Динамика показателей иммунного статуса и ригидности сосудистой стенки у больных артериальной гипертензией с ожирением. Фундаментальные исследования. 2012;7(2):338-43.[ Knyazeva LI, Shishova AS, Stepchenko MA. Dynamics of indices of immune status and rigidity of the vascular wall in patients with arterial hypertension with obesity. Fundamental'nyye Issledovaniya. 2012;7(2):338-43 (In Russ.)].; McLeanRR Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134-9. doi:10.1007/s11914-009-0023-2; Кремнева ЛВ, Шалаев СВ. Липопротеины низкой плотности и воспаление как факторы риска ИБС. Плейотропные эффекты статинов в профилактике сердечно-сосудистых осложнений. Клиническая фармакология и фармакотерапия. 2003;(3):36-9 [Kremneva LV, Shalayev SV. Lipoproteins of low density and inflammation as risk factors for coronary heart disease. Pleiotropic effects of statins in the prevention of cardiovascular complications. Klinicheskaya Farmakologiya i Farmakoterapiya. 2003;(3):36-9 (In Russ.)].; Агеев ФТ, Баринова ИВ, Середенина ЕМ и др. Остеопороз; и жесткость артерий: исследование 103 женщин с умеренным и низким риском развития осложнений сердечно-сосудистых заболеваний. Кардиология. 2013;53(6):51-8 [Ageev FT, Barinova IV, Seredenina EM, et al. Osteoporosis and arterial stiffness: a study of 103 women with moderate and low risk of developing complications of cardiovascular disease. Kardiologiya. 2013;53(6):51-8 (In Russ.)].; Скрипникова ИА, Алиханова НА, Ткачева ОН и др. Минеральная плотность кости и состояние сосудистой стенки в зависимости от статуса репликативного клеточного старения; у женщин в постменопаузальном периоде. Остеопороз и остеопатии. 2015;(3):13-7 [Alikhanova NA, Skripnikova IA, Tkacheva ON, et al. Mineral bone density and the state of the vascular wall, depending on the status of replicative cell aging in postmenopausal women. Osteoporoz i Osteopatii = Osteoporosis and Ostheopathy. 2015;(3):13-7 (In Russ.)].; Ouchi Y, Akashita M, de Souza AC, et al. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recomended dietary allowance of calcium in the eldery. Ann NY Acad Sci. 1993;(676):297-307. doi:10.1111/j.1749-6632.1993.tb38743.x; Manna DL, Young JB. Basic mechanism in congestive heart failure. Recognising the role proinflamatory cytokines. Chest. 1994;105:897-904. doi:10.1378/chest.105.3.897; Ершова ОБ, Баранов АА, Новикова ИВ и др. Уровень ИЛ-6; и интерлейкина-17 у женщин в постменопаузе: связь с показателями минеральной плотности костной ткани и кардиоваскулярной патологией. Вестник Ивановской медицинской академии. 2012;17(2):71-2 [Ershova OB, Baranov AA, Novikova IV, et al. The level of IL-6 and interleukin-17 in postmenopausal women: a relationship with indicators of bone mineral density and cardiovascular pathology. Vestnik Ivanovskoj Medicinskoj Akademii. 2012;17(2):71-2 (In Russ.)].; Inoue T, Komoda H, Nokana M, et al. Interleukin-8 as an independent predictor of long-term clinical outcome in patient with coronary artery disease. Int J Cardiol. 2008;124(3):319-25.; Pestka S, Krause CD, Sarkar D, et al. IL-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929-79.; Pfeilschifter J, Kö ditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocrine Rev. 2002;23:90-119. doi:10.1210/edrv.23.1.0456; Gertz ER, Silverman NE, Wise KS, et al. Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation. J Clin Densitom. 2010 Jul-Sep;13(3):277-82. doi:10.1016/j.jocd.2010.04.003

  17. 17
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 56, No 1 (2018); 41-47 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 41-47 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2498/1656; Alemao E, Cawston H, Bourhis F, et al. Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology (Oxford). 2016 May;55(5):809-16. doi:10.1093/rheumatology/kev427; Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. doi:10.1016/j.acvd.2010.03.007; Горбунова ЮН, Новикова ДС, Попкова ТВ и др. Кардиоваскулярный риск у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии (предварительные данные исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4):381-6 [Gorbunova YuN, Novikova DS, Popkova TV, et al. Cardiovascular risk in patients with early rheumatoid arthritis before disease-modifying antirheumatic therapy (preliminary data of the REMARCА study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):381-6 (In Russ.)]. doi:10.14412/1995-4484-2014-381-386; Удачкина ЕВ, Новикова ДС, Попкова ТВ и др. Динамика липидных параметров крови у больных ранним ревматоидным артритом на фоне противоревматической терапии, проводимой по принципу «Лечение до достижения цели» (по данным 18-месячного наблюдения). Научнопрактическая ревматология. 2016;54(2):164-70 [Udachkina EV, Novikova DS, Popkova TV, et al. Time course of changes in blood lipid parameters in patients with early rheumatoid arthritis during treat-to-target antirheumatic therapy: According to 18-month follow-up findings. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):164-70 (In Russ.)]. doi:10.14412/1995-4484-2016-164-170; Попкова ТВ, Новикова ДС, Насонов ЕЛ. Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2016;54(2):122-8 [Popkova TV, Novikova DS, Nasonov EL. Cardiovascular diseases in rheumatoid arthritis: Latest data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):1228 (In Russ.)]. doi:10.14412/1995-4484-2016-122-128; Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012 Mar;30(3):445-8. doi:10.1097/HJH.0b013e32834fa8b0; Laurent S, Cockcroft J, van Bortel LM, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-605. doi:10.1093/eurheartj/ehl2542006; Vazquez-Del MM, Gomez-Banuelos E, Chavarria-Avila E, et al. Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article. Medicine (Baltimore). 2017 Aug;96(33):e7862. doi:10.1097/MD.0000000000007862; Ambrosino P, Lupoli R, Di Minno A, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015 May;113(5):916-30. doi:10.1160/TH14-11-0921. Epub 2015 Feb 26.; Arida A, Zampeli E, Konstantonis G, et al. Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors. Clin Rheumatol. 2015 May;34(5):853-9. doi:10.1007/s10067-0152914-1. Epub 2015 Mar 11.; Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008 Oct;121(10 Suppl 1):S21-31. doi:10.1016/j.amjmed.2008.06.014; Arida A, Protogerou AD, Konstantonis G, et al. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017 Jun 1;56(6):934-9. doi:10.1093/rheumatology/kew506; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi:10.1136/annrheumdis-2013-204573; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научнопрактическая ревматология. 2016;54(5):557-71 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and International guidelines. A pilot study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):557-71 (In Russ.)]. doi:10.14412/1995-4484-2016557-571; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-44842014-477-494; Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011,Mar;50(3):518-31. doi:10.1093/rheumatology/keq316; Mäki-Petäjä KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des. 2009;15(3):290-303. doi:10.2174/138161209787354221; Князева ЛА, Мещерина НС. Влияние инфликсимаба на параметры ремоделирования артериального русла, уровень RANKL и остеопротегерина у больных ревматоидным артритом. Научно-практическая ревматология. 2013;51(6):666-70 [Knyazeva LA, Meshcherina NS. Effect of infliximab on parameters of remodeling of arterial bloodstream, RANKL and osteoprotegerin levels in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):666-70 (In Russ.)]. doi:10.14412/1995-4484-2013-666-70; Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid arthritis: results from the TEAR trial. Arthritis Rheum. 2013;65(6):1430-8. doi:10.1002/art.37916 12; Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007 Nov;66(11):1503-7. doi:10.1136/ard.2006.066191; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМАПРЕСС; 2013. 549 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 549 p.].; Sandoo A, Hodson J, Douglas KM, et al. The association between functional and morphological assessments of endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2013;15(5):R107. doi:10.1186/ar4287; Kiortsis DN, Mavridis AK. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis. 2006;33:4921-3.; Yun H, Xie F, Delzell E, et al. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. Br J Clin Pharmacol. 2015 Dec;80(6):1447-57. doi:10.1111/bcp.12709; Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016 Feb;96(2):207-12. doi:10.2340/00015555-2214; Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2(4):428-39. doi:10.4161/mabs.12304; Voulgari PV. Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. doi:10.1517/14728214.13.1.175; Чичасова НВ. Ингибитор фактора некроза опухоли α голимумаб в лечении ревматоидного артрита. Современная ревматология. 2014;(4):76-85 [Chichasova NV. The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(4):76-85 (In Russ.)]. doi:10.14412/1996-7012-2014-4-76-85; Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10 (Прил. 2):64 [Cardiovascular prevention: national guidelines. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2011;10 Suppl 2:64 (In Russ.)].; Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345-52.; Парфенов АС. Экспресс-диагностика сердечно-сосудистых заболевавний. Мир измерений. 2008;(6):74-82. [Parfenov AS. Express diagnostics of cardiovascular zabolevaniy. Mir Izmerenii = World Measurements. 2008;(6):74-82 (In Russ.)].; Мельникова ЛВ. Значение гемодинамических факторов в развитии ремоделирования сосудов мышечноэластического типа при артериальной гипертензии. Саратовский научно-медицинский журнал. 2011;7(1):76-9 [Melnikova LV. Importance of hemodynamic factors in vascular remodeling of muscular elastic type in arterial hypertension. Saratovskii Nauchno-Meditsinskii Zhurnal = Saratov Journal of Medical Scientific Research. 2011;7(1):76-9. (In Russ.)].; Dalbeni A, Giollo A, Tagetti A, et al. Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients? Int J Cardiol. 2017, Jan 14. pii: S0167-5273(16)33190-4. doi:10.1016/j.ijcard.2017.01.072. [Epub ahead of print].; Новикова ДС, Попкова ТВ, Кириллова ИГ и др. Оценка кардиоваскулярного риска у больных ранним ревматоидным артритом в рамках исследования РЕМАРКА (предварительные данные). Научно-практическая ревматология. 2015;53(1):24-31 [Novikova DS, Popkova TV, Kirillova IG, et al. Cardiovascular risk assessment in patients with early rheumatoid arthritis within the REMARCA study: Preliminary data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):24-31 (In Russ.)]. doi:10.14412/1995-4484-2015-24-31; Van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011;40:389-97. doi:10.1016/ j.semarthrit.2010.06.006; Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014 Jan;73(1):161-9. doi:10.1136/annrheumdis-2012-202089; Bathon J, Wasko MC, Kirkham B, et al. Golimumab and cardiovascular disease: carotid artery ultrasound evaluation and cardiovascular adverse events. Ann Rheum Dis. 2010;69 (Suppl 3):464.; Wasko MC, Hsia EC, Kirkham B, et al. Effect of Golimumab on Carotid Atherosclerotic Disease Measures and Cardiovascular Events in Inflammatory Arthritides. J Clin Rheumatol. 2014 Jan;20(1):1-10. doi:10.1097/RHU.0000000000000053

  18. 18
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 5 (2018); 711-715 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 5 (2018); 711-715 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-5

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1760/1720; Sritheran D., Leung Y.Y. Making the next steps in psoriatic arthritis management: current status and future directions. Ther Adv Musculoskelet Dis. 2015;7(5):173-86. doi:10.1177/1759720X15595966.; Ritchlin C.T. Pathogenesis of psoriatic arthritis. Сurr Opin Rheumatol. 2005;17(4):406-12. doi:10.1097/01.bor.0000167752.93543.76.; Polachek A., Touma Z., Anderson M. et al. Risk of Cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69(1):67-74. doi:10.1002/acr.22926.; Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:1074-80. doi:10.1002/art.22884.; Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:287-93. doi:10.1002/art.22530.; Ahlehoff O., Skov L., Gislason G. et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128-34. doi:10.1111/jdv.12768.; Kohm M., Burkhardt H., Behrens F. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5):109-14.; Tam L.S., Li E.K., Shang Q. et al. Tumor necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis. 2011;70:705-6. doi:10.1136/ard.2010.131359.; Mazzoccoli G., Notarsanto I., de Pinto G.D. et al. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med. 2010;5(6):495-500. doi:10.1007/s11739-010-0458-6.; Ramonda R., Puato M., Punzi L. et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine. 2014;81(5):421-5. doi:10.1016/j.jbspin.2014.02.005.; Zhao Q., Hong D., Zhang Y., et al. Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94(14):e731. doi:10.1097/MD.0000000000000731.; Grossman C., Bornstein G., Leibowitz A., et al. Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. Blood Press. 2017;26(1):24-9. doi:10.1080/08037051.2016.1183460.; Sandoo A., Panoulas V.F., Toms T.E., et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011;25(11):699-702. doi:10.1038/jhh.2011.36.; Chandran V., Schentag C.T., Gladman D.D. Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. J Rheumatol. 2008;35(10):2069-70. PMID:18843760; Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: aproposedobjectivetarget for treatment. Ann Rheum Dis. 2010;69(1):48-53. doi:10.1136/ard.2008.102053.; Амирджанова В.Н., Катлубава Г.М., Горячев Д.В. и др. Валидация русско-язычной версии HAQ. Научно-практическая Ревматология. 2004;2:50-6.; Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207-74. doi:10.1714/2729.27821.; Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. doi:10.1097/01.hjh.0000431740.32696.cc.; Tam L.S., Kitas G.D., Gonzalez-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 2014;53:1108-19. doi:10.1093/rheumatology/ket454.; de La Forest Divonne M., Gottenberg J.E., Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine 2017;84(2):133-40. doi:10.1016/j.jbspin.2016.02.028.; Bissonnette R., Harel F., Krueger J.G. et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: A Randomized Placebo-Controlled Study. J Invest Dermatol. 2017;137(8):1638-45. doi:10.1016/j.jid.2017.02.977.; Mehta N.N., Shin D.B., Joshi A.A., et al. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ Cardiovasc Imaging. 2018;11(6):e007394. doi:10.1161/CIRCIMAGING.117.007394.; Smolen J., Landewe R.B., Mease P. et al. Efficacy and safety of certolizumabpegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68:797-804. doi:10.1136/ard.2008.101659.; https://www.rpcardio.com/jour/article/view/1760

  19. 19
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 14, No 2 (2018); 210-216 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 2 (2018); 210-216 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1650/1624; Tavazzi L., Senni M., Metra M., et al. Multicenter prospective observational study on acute and chronic heart failure: the one-year follow-up results of IN-HF outcome registry. Circ Heart Fail. 2013;6:47381. doi:10.1161/CIRCHEARTFAILURE.112.000161.; Maggioni A.P., Dahlstrom U., Filippatos G., et al. on behalf of the Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:80817. doi:10.1093/eurjhf/hft050.; Jhund P.S., Macintyre K., Simpson C.R., et al. Long-term trends in fist hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515-23. doi:10.1161/CIRCULATIONAHA.108.812172.; Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.; Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):137-61. doi:10.1161/CIR.0000000000000509.; Braunwald E. The path to an angiotensin receptor antagonist neprilysin inhibitor in the treatment of heart failure. J Am CollCardiol. 2015;65:1029-41. doi:10.1016/j.jacc.2015.01.033.; Braunwald E. Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure. Eur Heart J. 2016;37:745-6. doi:10.1093/eurheartj/ehw055.; McMurray J., Packer M., Desai A., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность (ХСН) Клинические рекомендации (2016). Доступно на: http://scardio.ru/content/Guidelines/SSHF-Guidelines-rev.4.0.1.pdf. Проверено 16.04.2018.; Elzinga G., Westerhof N. Matching between ventricle and arterial load: an evolutionary process. Circ Res. 1991;68:1495-1500. doi:10.1161/01.RES.68.6.1495.; Sunagawa K., Maughan W.L., Sagawa K. Optimal arterial resistance for the maximal stroke studied in isolated canine left ventricle. Circ Res. 1985;56:586-95. doi:10.1161/01.RES.56.4.586.; Chantler P.D., Lakatta E.G., Najjar S.S. Arterial-ventricular coupling: Mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol. 2008;105:1342-51. doi:10.1152/japplphysiol.90600.2008.; Asanoi H., Sasayama S., Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. Circulation Research. 1989;65:483-93. doi:10.1161/01.RES.65.2.483.; Vlachopoulos C., Aznaouridis K., O’Rourke M.F., et al. Prediction of cardiovascular events and allcause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865-871. doi:10.1093/eurheartj/ehq024.; McEniery C.M., Cockcroft J.R., Roman M.J., et al. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014,35:1719-25. doi:10.1093/eurheartj/eht565.; Williams B., Lacy P.S. Central aortic pressure and clinical outcomes. J Hypertens. 2009;27:1123-5. doi:10.1097/HJH.0b013e32832b6566.; Ky B., French B., May Khan A., et al. Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol. 2013;62:1165-72. doi:10.1016/j.jacc.2013.03.085.; Hoffman J.I., Buckberg G.D. The myocardial supply: demand ratio: a critical review. Am J Cardiol. 1978;41:327-32. doi:10.1016/0002-9149(78)90174-1.; Williams B., Cockcroft J.R., Kario K., et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension The PARAMETER Study. Hypertension. 2017;69:411-20. doi:10.1161/HYPERTENSIONAHA.116.08556.; Iborra-Egea O., Galvez-Monton C., Roura S., et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017;3:12. doi:10.1038/s41540-017-0013-4.; Hoskova L., Melenovsky V., Kautzner J., et al. Cardioprotective effect of LCZ696 versus valsartan on left ventricular remodeling in experimental model of chronic heart failure. Eur J Heart Failure. 2017;19 (Suppl. 1):168-9 (P640); Maurin V., Canu A., Bernard A., et al. Early reverse remodeling and improvement of echo parameters after introduction of sacubitril/valsartan in 80 stable and well treated HFrEF patients. Eur J Heart Failure. 2017;19(Suppl. 1):296 (P1189).; https://www.rpcardio.com/jour/article/view/1650

  20. 20